Literature DB >> 14117810

METABOLIC EFFECTS OF 9-D-ARABINOSYLPURINES IN ASCITES TUMOR CELLS.

J J BRINK, G A LEPAGE.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS; CARBON ISOTOPES; DNA, NEOPLASM; EXPERIMENTAL LAB STUDY; LEUKEMIA L1210; MICE; NEOPLASMS, EXPERIMENTAL; PURINES; RNA, NEOPLASM

Mesh：

Substances：

Year:  1964        PMID： 14117810

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  9 in total

1.  Herpesvirus hominis infection in newborn mice: comparison of the therapeutic efficacy of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyladenine.

Authors:  E R Kern; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  Effect of cytosine arabinoside, adenine arabinoside, tilorone, and rifamycin SV on multiplication of Herpesvirus saimiri in vitro.

Authors:  R H Adamson; D V Ablashi; G R Armstrong; N W Ellmore
Journal:  Antimicrob Agents Chemother       Date:  1972-01       Impact factor: 5.191

4.  Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancer.

Authors:  A Mittelman; S Savona; C Puccio; H Chun; T Ahmed; E Feldman; P Sullivan; P Arnold; Z Arlin
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

5.  Selective inhibition of nuclear DNA synthesis by 9- -D-arabinofuranosyl adenine in rat cells transformed by Rous sarcoma virus.

Authors:  C Shipman; S H Smith; J C Drach
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

6.  Phase I clinical trial of fludarabine phosphate (F-ara-AMP).

Authors:  E S Casper; A Mittelman; D Kelson; C W Young
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Thermal inactivation as a means of inhibiting the serum-associated deamination of 9-beta-D Arabinofuranosyladenine in tissue culture media.

Authors:  P M Schwartz; C Shipman; R H Carlson; J C Drach
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

8.  Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer.

Authors:  A Mittelman; R Ashikari; T Ahmed; S Savona; P Arnold; Z Arlin
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.

Authors:  L Danhauser; W Plunkett; M Keating; F Cabanillas
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.